Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

354 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Demaria O, De Gassart A, Coso S, Gestermann N, Di Domizio J, Flatz L, Gaide O, Michielin O, Hwu P, Petrova TV, Martinon F, Modlin RL, Speiser DE, Gilliet M. Demaria O, et al. Among authors: de gassart a, speiser de. Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15408-13. doi: 10.1073/pnas.1512832112. Epub 2015 Nov 25. Proc Natl Acad Sci U S A. 2015. PMID: 26607445 Free PMC article.
Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life.
Rubio-Godoy V, Dutoit V, Rimoldi D, Lienard D, Lejeune F, Speiser D, Guillaume P, Cerottini JC, Romero P, Valmori D. Rubio-Godoy V, et al. Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10302-7. doi: 10.1073/pnas.181348898. Epub 2001 Aug 21. Proc Natl Acad Sci U S A. 2001. PMID: 11517329 Free PMC article.
Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.
Romero P, Valmori D, Pittet MJ, Zippelius A, Rimoldi D, Lévy F, Dutoit V, Ayyoub M, Rubio-Godoy V, Michielin O, Guillaume P, Batard P, Luescher IF, Lejeune F, Liénard D, Rufer N, Dietrich PY, Speiser DE, Cerottini JC. Romero P, et al. Among authors: speiser de. Immunol Rev. 2002 Oct;188:81-96. doi: 10.1034/j.1600-065x.2002.18808.x. Immunol Rev. 2002. PMID: 12445283 Review.
Tinkering with nature: the tale of optimizing peptide based cancer vaccines.
Michielin O, Blanchet JS, Fagerberg T, Valmori D, Rubio-Godoy V, Speiser D, Ayyoub M, Alves P, Luescher I, Gairin JE, Cerottini JC, Romero P. Michielin O, et al. Cancer Treat Res. 2005;123:267-91. doi: 10.1007/0-387-27545-2_12. Cancer Treat Res. 2005. PMID: 16211875 Review. No abstract available.
The human T cell response to melanoma antigens.
Romero P, Cerottini JC, Speiser DE. Romero P, et al. Among authors: speiser de. Adv Immunol. 2006;92:187-224. doi: 10.1016/S0065-2776(06)92005-7. Adv Immunol. 2006. PMID: 17145305 Review.
Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients.
Alves PM, Viatte S, Fagerberg T, Michielin O, Bricard G, Bouzourene H, Vuilleumier H, Kruger T, Givel JC, Lévy F, Speiser DE, Cerottini JC, Romero P. Alves PM, et al. Among authors: speiser de. Cancer Immunol Immunother. 2007 Nov;56(11):1795-805. doi: 10.1007/s00262-007-0323-2. Epub 2007 Apr 20. Cancer Immunol Immunother. 2007. PMID: 17447064 Free PMC article.
354 results